AI Article Synopsis
- Sialorrhea, or excessive drooling, is a common issue among patients with Parkinson's disease (PD), and this study aimed to investigate how deep brain stimulation of the subthalamic nucleus (STN-DBS) impacts its occurrence.
- In a multicenter clinical trial involving 170 patients with advanced PD, researchers compared those receiving STN-DBS to those on medication therapy, focusing on long-term sialorrhea outcomes.
- Results showed that a higher percentage of patients receiving STN-DBS experienced sialorrhea compared to those on medication, indicating that STN-DBS may increase the risk of drooling in these patients.
Article Abstract
Introduction: Sialorrhea is a common neurological manifestation of Parkinson's disease (PD). No specifically designed prospective study has tested the effects of deep brain stimulation of the subthalamic nucleus (STN-DBS) on sialorrhea in patients with advanced PD. We focused on the effect of STN-DBS on the incidence of sialorrhea in patients with PD.
Methods: This multicenter, prospective, non-randomized concurrent clinical trial analyzed the incidence of sialorrhea during long-term follow-up in 170 patients with advanced PD (84 patients with STN-DBS and 86 patients with medication therapy).
Results: After STN-DBS, 58.1% of patients presented with sialorrhea (Drooling Rating Scale (DRS) > 5) compared with 39.3% of patients with medication therapy (P < 0.001). STN-DBS stimulation demonstrated a significant increase in DRS and Drooling Severity and Frequency Scale (DSFS) compared with the patients with medication therapy (P < 0.001). At follow-up, the onabotulinumtoxin-A (BTX-A) injection ratio was significantly higher in the STN-DBS group (29.8% vs. 11.9%, P = 0.0057) compared with the patients with medication therapy.
Conclusions: STN-DBS increased the risk of sialorrhea in patients with advanced PD.
Trial Registration: clinicaltrials. gov (NCT06090929).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.parkreldis.2024.106075 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of obstructive sleep apnea risk on sialorrhea in patients with Parkinson's disease.
Sleep Breath
January 2025
Gülhane School of Medicine, Department of Neurology, University of Health Sciences, Ankara, Türkiye.
Background: Our aim was to determine the effect of obstructive sleep apnea syndrome (OSAS) risk on sialorrhea in patients with Parkinson's disease (PD).
Methods: A total of 75 patients with PD (mean age 66.36 ± 8.
Clozapine and Pneumonia: Synthesizing the Link by Reviewing Existing Reports-A Systematic Review and Meta-Analysis.
Medicina (Kaunas)
December 2024
Department of Psychiatry, University of Melbourne, Parkville 3052, Australia.
Clozapine is a highly effective antipsychotic used for treating treatment-refractory psychotic and mood disorders. However, clozapine also has a serious risk of side effects leading to mortality, particularly its potentiated risk of leading to pneumonia. This review aims to overview the demographic and health-related risk factors leading to pneumonia to better inform risk assessment for clozapine users and to summarise current theories on the mechanisms for clozapine-associated pneumonia.
View Article and Find Full Text PDFThe effectiveness and safety of botulinum toxin treatment for sialorrhea due to severe brain injury.
Brain Inj
January 2025
Brain Injury Services, Royal Hospital for Neurodisability, London, UK.
Introduction: Sialorrhea may be a consequence of severe acquired brain injury (ABI). Salivary gland botulinum neurotoxin (SG-BoNT) injections can reduce saliva production, but there is limited evidence for their use in ABI.We reviewed the effectiveness, impact on chest infection frequency, and safety of SG-BoNT for sialorrhea in a cohort of patients with severe ABI.
View Article and Find Full Text PDFClozapine-Associated Sialorrhea: A Literature Review.
J Clin Psychopharmacol
October 2024
TOBB University of Economics and Technology, Faculty of Medicine, Ankara, Turkey.
Background: Clozapine has demonstrated efficacy in treating treatment-resistant schizophrenia; however, it has a wide range of side effects. Sialorrhea is a common side effect of clozapine that causes the patient to withdraw from social life. This review aims to evaluate and summarize the prevalence, mechanism, risk factors, and management of clozapine-associated sialorrhea.
View Article and Find Full Text PDFOptimization of Clozapine Treatment: Study of Variables Affecting Response in Uruguayan Patients With Schizophrenia.
J Clin Psychopharmacol
December 2024
Human Molecular Genetics Laboratory, Institut Pasteur de Montevideo.
Purpose/background: Clozapine is the recommended drug for treatment-resistant schizophrenia. Drug response could be affected by numerous factors such as age, sex, body mass index, co-medication, consumption of xanthine-containing beverages, smoking, and genetic variants of the enzymes involved in clozapine metabolism (CYP1A2, CYP3A4, and, to a lesser extent, CYP2C19 and CYP2D6). This study evaluated genetic and nongenetic variables that may affect clozapine plasma concentrations in Uruguayan patients with schizophrenia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!